3 Stocks Improving Performance Of The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 59 points (0.3%) at 18,083 as of Monday, May 4, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,918 issues advancing vs. 1,077 declining with 158 unchanged.

The Health Care sector currently sits up 1.2% versus the S&P 500, which is up 0.4%. Top gainers within the sector include Intercept Pharmaceuticals ( ICPT), up 5.3%, ISIS Pharmaceuticals ( ISIS), up 4.1%, Incyte ( INCY), up 3.6%, St Jude Medical ( STJ), up 2.1% and Fresenius Medical Care AG & Co. KGaA ( FMS), up 2.1%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Biogen ( BIIB) is one of the companies pushing the Health Care sector higher today. As of noon trading, Biogen is up $2.13 (0.6%) to $388.35 on average volume. Thus far, 785,170 shares of Biogen exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $387.01-$393.89 after having opened the day at $389.45 as compared to the previous trading day's close of $386.22.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen has a market cap of $88.0 billion and is part of the drugs industry. Shares are up 13.8% year-to-date as of the close of trading on Friday. Currently there are 12 analysts who rate Biogen a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire